Akebia Therapeutics, Inc. (AKBA) stock
AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.47−0.02 (-4.78%)
Close on Nov 13, 2026Market cap $131.40MP/E –Yield –
Akebia Therapeutics statistics
88 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Last ex-dividend date
- No dividends
- Fundamentals through
- Sep 30, 2026
- Share price as of
- Nov 13, 2026
Valuation ratiosIndustry
- P/OCF Ratio
- 8.33
- 12.99
Enterprise valuationIndustry
- EV / Sales
- 0.11
- 2.57
- EV / FCF
- 1.62
- 22.27
Share statisticsIndustry
- Shares Change (YoY)
- 4.80%
- 10.8%
- Shares Change (QoQ)
- 2.12%
- 0.50%
- Float
- 269M
- 49M
- Shares Held by Insiders
- 2.95%
- 11.7%
- Shares Held by Institutions
- 39.7%
- 56.4%
Short sellingIndustry
- Short Interest
- 27M
- –
- Short Interest Change
- 17.9%
- -0.80%
- Short % of Float
- 10.1%
- 9.01%
- Short % of Shares Outstanding
- 9.82%
- 6.30%
- Days to Cover
- 3.01
- 5.15
Stock price statisticsIndustry
- 52-Week High
- $1.83
- –
- 52-Week Low
- $0.36
- –
- 20-Day Moving Average
- $0.61
- –
- 50-Day Moving Average
- $0.77
- –
- 200-Day Moving Average
- $1.10
- –
- Average True Range (14)
- $0.08
- –
- Price Change (1 Week)
- 18.2%
- -1.15%
- Price Change (1 Month)
- -31.8%
- -4.87%
- Price Change (3 Months)
- -44.9%
- -21.0%
- Price Change (6 Months)
- -55.3%
- -20.6%
- Price Change (YTD)
- -70.5%
- -23.6%
- Price Change (1 Year)
- -74.4%
- -22.4%
- Price Change (3 Years)
- -54.0%
- -29.5%
- Price Change (5 Years)
- -83.5%
- -77.9%
- Price Change (10 Years)
- -94.7%
- -65.4%
- Average Volume (10 Days)
- 9M
- –
- Average Volume (20 Days)
- 9M
- –
- Average Volume (90 Days)
- 7M
- –
- Relative Volume
- 0.56
- 0.70
- Relative Strength Index (14)
- 36.5
- 43.4
- Volatility (1 Year)
- 89.5%
- 80.1%
- Beta (5 Years)
- 1.10
- 1.07
MarginsIndustry
- Pretax Margin
- -21.9%
- -11.6%
- EBITDA Margin
- -15.7%
- -27.7%
- FCF Margin
- 7.03%
- -9.56%
Returns on capitalIndustry
- Return on Equity (ROE)
- -143.8%
- -49.9%
- Return on Assets (ROA)
- -12.6%
- -40.6%
- Return on Capital Employed (ROCE)
- -17.3%
- -37.9%
Financial positionIndustry
- Current Ratio
- 1.36
- 3.30
- Quick Ratio
- 1.21
- 2.39
- Debt / Equity
- 2.47
- 0.49
- Debt / FCF
- 3.63
- 4.65
GrowthIndustry
- Revenue Growth (YoY)
- -12.4%
- 6.82%
- FCF Growth (YoY)
- -56.9%
- 6.85%
- Revenue Growth (3Y CAGR)
- -6.88%
- 2.25%
- Revenue Growth (5Y CAGR)
- -4.33%
- 6.41%
EfficiencyIndustry
- Asset Turnover
- 0.56
- 0.40
- Inventory Turnover
- 2.23
- 2.73
- Revenue Per Employee
- $1.02M
- $429.29K
- Profits Per Employee
- -$229.69K
- -$689.41K
- Employee Count
- 194
- 74
- WACC
- 9.21%
- 10.2%
Income statement (TTM)Industry
- Pretax Income
- -$43.18M
- -$12.95M
Balance sheetIndustry
- Net Cash (Debt)
- $108.98M
- $17.76M
- Net Cash Per Share
- $0.39
- $0.80
- Equity (Book Value)
- $20.37M
- $53.89M
- Book Value Per Share
- $0.07
- $1.50
- Tangible Book Value
- -$38.68M
- $27.13M
- Working Capital
- $58.44M
- $79.99M
Cash flow (TTM)Industry
- Capital Expenditures
- -$1.92M
- -$1.00M
- FCF Per Share
- $0.05
- -$0.42
Dividends and yieldsIndustry
- Earnings Yield
- -33.9%
- -21.8%
- FCF Yield
- 10.5%
- -9.44%
Taxes and interestIndustry
- Income Tax
- $1.38M
- $73.00K
Scores and fair valueIndustry
- Altman Z-Score
- -6.30
- 0.23
- Piotroski F-Score
- 7
- 4
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | AKBA | S&P 500 | Difference | AKBA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -38.4% | -3.0% | −35.4 pts | ||
| 3 months | -45.5% | -2.8% | −42.7 pts | ||
| Year to date | -70.5% | +11.5% | −82.0 pts | ||
| 1 year | -73.1% | +13.5% | −86.5 pts | ||
| 3 years | -48.6% | +77.7% | −126.3 pts | -19.9% | +21.1% |
| 5 years | -83.5% | +72.6% | −156.1 pts | -30.2% | +11.5% |
| 10 years | -94.6% | +308.2% | −402.8 pts | -25.3% | +15.1% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
27M AKBA shares were sold short on Oct 30, 2026, up 17.9% from the previous report, or 10.12% of the shares available to trade. At recent volumes it would take 3.0 days to buy them back. Over the last 20 sessions, 65.6% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 27,204,975 | +17.9% | 9,051,604 | 3.0 |
| Oct 15, 2026 | 23,071,255 | +2.6% | 7,794,014 | 3.0 |
| Sep 30, 2026 | 22,481,147 | +9.6% | 6,412,381 | 3.5 |
| Sep 15, 2026 | 20,504,915 | -10.9% | 7,439,437 | 2.8 |
| Aug 31, 2026 | 23,002,561 | +7.6% | 9,826,387 | 2.3 |
| Aug 14, 2026 | 21,371,566 | +11.4% | 6,044,103 | 3.5 |
| Jul 31, 2026 | 19,183,020 | +0.6% | 2,177,153 | 8.8 |
| Jul 15, 2026 | 19,076,806 | -0.5% | 4,543,375 | 4.2 |
| Jun 30, 2026 | 19,177,371 | -34.3% | 7,120,957 | 2.7 |
| Jun 15, 2026 | 29,201,925 | +6.5% | 5,214,571 | 5.6 |
| May 29, 2026 | 27,420,606 | +4.0% | 6,624,978 | 4.1 |
| May 15, 2026 | 26,371,163 | -4.5% | 4,638,423 | 5.7 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?